Compare BridgeBio Pharma Inc (BBIO) vs Core Scientific Inc (CORZ) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

Core Scientific (CORZ) trades at $22.71, down 3.32% today, with a bearish technical signal despite strong analyst support. The company is transitioning from Bitcoin mining to AI colocation, with Q1 2026 colocation revenue surging to $77.5M and gross margins of 57%. However, the company continues to report significant losses with a net income margin of -341.68% and negative cash flow of $525.6M in 2025.

The outlook remains speculative with substantial execution risk despite analyst optimism. While the AI pivot offers growth potential, persistent losses and cash burn present significant challenges. The consensus price target of $34.17 suggests 50% upside potential, but investors must weigh the high-risk transformation against the company's current financial instability.